Engage SOF (eSOF) Capabilities of Interest – U.S. Special Operations Command (USSOCOM)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

USSOCOM’s Engage SOF (eSOF) program provides a rolling pathway for companies to submit technologies aligned with Special Operations Forces (SOF) capability needs. Selected solutions may receive funding through contracts, OTAs, SBIR/STTR, or other mechanisms. Submissions are open through December 31, 2026.

How much funding would I receive?

Estimated $500K to $5 Million - Funding is not fixed. Awards vary depending on the pathway and may include contracts, OTAs, SBIR/STTR, CRADAs, or prize competitions.

What could I use the funding for?

Projects must align with USSOCOM Capabilities of Interest (CoIs), including (full list here):

• Aviation Systems

• Biometrics and Forensics

• Command, Control, Communications, and Computers (C4)

• Cyberspace Operations

• Human Performance/Human Machine Interface

• Information Operations

• Intelligence, Surveillance, and Reconnaissance (ISR)

• Irregular Warfare

• Medical Technology

• Canine Medicine

• Mobility

• Power and Energy

• Soldier Systems

• Weapons and Electronic Attack

Are there any additional benefits I would receive?

Beyond direct funding, there are significant indirect benefits:

Government Validation and Credibility: Selection by USSOCOM signals strong alignment with real-world defense needs and increases trust with DoD stakeholders, primes, and investors.

Direct Access to End Users: eSOF connects companies directly with Program Executive Offices, Directorates, and operators for real-world feedback and validation.

Multiple Contracting Pathways: Companies can transition into OTAs, FAR contracts, CRADAs, or prototype programs without starting from scratch.

Follow-on Opportunities: Successful technologies may progress into experimentation, prototyping, and eventual procurement pathways.

Stronger Exit Potential: Government-backed validation and nondilutive funding can significantly increase company valuation and acquisition interest.

What is the timeline to apply and when would I receive funding?

Submissions are accepted on a rolling basis from March 26, 2026 through December 31, 2026.

Funding timing varies depending on the pathway and evaluation process after submission.

Where does this funding come from?

Funding comes from U.S. Special Operations Command (USSOCOM) and is executed through various federal acquisition and research mechanisms including OTAs, FAR contracts, SBIR/STTR, and others.

Who is eligible to apply?

Any organization capable of providing relevant commercial technologies may apply. Submissions must present unclassified information and align with published Capabilities of Interest.

What companies and projects are likely to win?

• Clearly match one or more published Capabilities of Interest

• Demonstrate strong technical maturity and real-world applicability

• Show measurable impact on SOF mission effectiveness

• Meet security and compliance requirements

• Provide evidence supporting performance and readiness

Are there any restrictions I should know about?

• Submissions must be UNCLASSIFIED

• Solutions must align with current Capabilities of Interest to be prioritized

• May require CMMC compliance and security vetting

• Some pathways may involve classified applications and facility clearance requirements

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

1. Triple your likelihood of success through proven strategy and insider-aligned proposal development

2. Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

3. Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($15,000 + 5%) available (Only $4,000 for preliminary application).

Additional Resources

Review the solicitation here (Requires Login).

Product Development Funding Programs – Cancer Prevention and Research Institute of Texas (CPRIT)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

CPRIT provides flexible, non-dilutive funding to support the development and commercialization of innovative cancer technologies. Through four distinct programs—SEED, TDDC, TTC, and TNTC—CPRIT funds companies across the full lifecycle, from early-stage discovery to late-stage clinical development. Preliminary applications are due April 16, 2026, with full applications due July 9, 2026.

How much funding would I receive?

Funding varies by program:

• SEED Awards: Up to ~$3 million (early-stage)

• TDDC, TTC, TNTC: No fixed cap; funding is flexible and negotiated based on project scope

CPRIT allocates approximately $70 million annually for company investments and distributes funding through milestone-based contracts tied to project progress

What could I use the funding for?

Funding supports research and development of technologies for the prevention, detection, diagnosis, monitoring, and treatment of cancer.

Common use cases include:

• Artificial intelligence and bioinformatics

• Therapeutics (drugs, biologics, cell therapies)

• Diagnostics and medical devices

• Manufacturing and biomanufacturing

• Clinical validation and trials

• Sample quality improvement and research tools

Which CPRIT Program is right for me?

CPRIT offers four programs designed for different stages and technology types:

SEED Awards (Earliest Stage)

• Focus: Preclinical and company formation

• Stage: Discovery → proof-of-concept

• Goal: De-risk early science and make the company investable

• Funding: Up to ~$3M

TDDC (Texas Diagnostic & Device Company Awards)

• Focus: Diagnostics and medical devices

• Stage: Late-stage development (near regulatory submission)

• Goal: Advance toward commercialization and market entry

TTC (Texas Therapeutics Company Awards)

• Focus: Therapeutics (drugs, biologics, cell therapies)

• Stage: IND-enabling through clinical development

• Goal: Advance clinical programs and regulatory approval

TNTC (Texas New Technologies Company Awards)

• Focus: Emerging and non-traditional technologies

• Stage: Varies

• Examples: AI, platforms, research tools, enabling technologies

• Goal: Support innovations that do not fit neatly into therapeutics or devices

What is the application process?

All CPRIT programs follow the same two-stage, competitive process:

Stage 1: Preliminary Application (Initial Screening)
Applicants submit:

• Abstract

• Executive summary (≤2 pages)

• Slide deck (≤16 slides)

• Project aims and budget

Applications are reviewed for scientific merit and alignment with CPRIT priorities. Only top applicants are invited to proceed.

Stage 2: Full Application (Deep Diligence)
Invited companies submit:

• Integrated product development plan (technical, clinical, regulatory)

• Full business plan (market, competition, commercialization, financials, IP)

• Timeline and milestones

• Management team and execution plan

Applicants present to an expert panel and undergo due diligence before final selection.

Final Decision Process

• Scientific and product review

• Due diligence

• Program Integration Committee review

• Final approval by CPRIT Oversight Committee

Funding is awarded via milestone-based contracts tied to performance.

What is the timeline to apply and when would I receive funding?

• Preliminary Application Opens: April 7, 2026

• Preliminary Application Deadline: April 16, 2026

• Full Application Invitation: June 2026

• Full Application Deadline: July 9, 2026

• Award Period: September 1, 2026 – August 31, 2027

Funding is deployed over multiple years based on milestone completion.

Where does this funding come from?

Funding is provided by CPRIT through $6 billion in Texas taxpayer-backed general obligation bonds dedicated to cancer research and commercialization.

Who is eligible to apply?

Applicants must be:

• Texas-based, for-profit companies (or willing to relocate)

• Able to meet Texas presence requirements (e.g., HQ, personnel, manufacturing, or clinical activity in Texas)

• Compliant with CPRIT eligibility rules

What companies and projects are likely to win?

• Address a significant unmet medical need

• Demonstrate strong technical validation

• Show a clear path to commercialization

• Have an experienced management team

• Present a credible regulatory and development strategy

Are there any restrictions I should know about?

• Must maintain a business presence in Texas or be willing to relocate to Texas upon selection for award

• Matching funds are required

• Indirect costs capped at ~5%

• Travel expenses are not reimbursable (can count as matching funds)

• Funding is milestone-based with reporting requirements

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

1. Triple your likelihood of success through proven strategy and insider-aligned proposal development

2. Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

3. Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($20,000 + 5%) available (Only $5,000 for preliminary application).

Additional Resources

Review the solicitation here.

NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research - Naval Research Laboratory (NRL)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Naval Research Laboratory (NRL) is seeking innovative basic and applied research proposals across a wide range of scientific and engineering disciplines. Organizations can submit White Papers through September 30, 2026, with potential follow-on contracts, grants, or other agreements awarded based on technical merit.

How much funding would I receive?

Est. $500k to $5 million.

What could I use the funding for?

Funding supports basic and applied research aligned with Navy priorities, including (verbatim/high-level categories from the BAA):

• Systems Directorate (e.g., radar, antennas, computational electromagnetics, information systems, AI/ML, human systems integration)

• Materials Science and Component Technology (e.g., energy storage, corrosion, materials processing, bio/chemical detection)

• Ocean and Atmospheric Science (e.g., ocean acoustics, remote sensing, environmental modeling)

• Space Technology (e.g., spacecraft systems, sensors, propulsion, hypersonics)

Specific topic areas include (selected verbatim examples):

• “Virtual simulations and mixed reality systems… situational awareness, and training”

• “Data management and exploitation technologies that apply emerging mathematics and machine learning techniques”

• “Multi-agent and multi-robot systems, reinforcement learning, game theory”

• “Electrochemical energy storage and conversion systems such as batteries and fuel cells”

• “Optical sciences… lasers, sensors, and photonic technologies”

• “Cyber security, cryptographic technologies, and high assurance computing”

• “Spacecraft payloads; spacecraft propulsion systems; advanced materials for spaceflight use”

Many More Topics are listed in the Solicitation (See below).

Are there any additional benefits I would receive?

Beyond the formal funding award, there are significant indirect benefits:

Government Validation and Credibility:
Being selected by the Naval Research Laboratory signals strong technical credibility and alignment with U.S. Navy and DoD priorities.

Access to Defense Ecosystem:
Awardees gain exposure to Navy researchers, program managers, and potential transition partners across defense and aerospace.

Flexible Contracting Pathways:
The BAA allows for multiple award mechanisms (contracts, grants, OTAs), enabling faster and more flexible engagement than traditional procurement.

Follow-On Funding Opportunities:
Successful projects may lead to additional funding phases or expanded research programs based on performance.

Increased Strategic Positioning:
Participation positions companies for future DoD funding, partnerships, and potential acquisition interest.

What is the timeline to apply and when would I receive funding?

• White Papers Due: September 30, 2026 (4:00 PM EDT)

• Rolling evaluation and invitation for full proposals after White Paper review

• Funding timing varies based on evaluation and award negotiations

Where does this funding come from?

Department of Defense (DoD) → Department of the Navy → Office of Naval Research (ONR) → Naval Research Laboratory (NRL)

Who is eligible to apply?

• Educational institutions

• Small businesses

• Small disadvantaged businesses

• Historically Black Colleges and Universities (HBCUs)

• Minority institutions

• Other qualified organizations

What companies and projects are likely to win?

Selections are based on:

• Technical merit and scientific quality of the proposed approach

• Relevance to NRL research priorities

• Potential benefit to the Government relative to cost

• Feasibility and innovation of the solution

• Cost realism and overall value

Are there any restrictions I should know about?

• Must submit a White Paper first before a full proposal

• Some topics may require security clearances or classified work

• Awards depend on availability of funding

• Government may select all, some, or none of proposals

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

1. Triple your likelihood of success through proven strategy and insider-aligned proposal development

2. Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

3. Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($15,000 + 5%) available.

Additional Resources

Review the solicitation here.

Low Power Seawater Converter for Aircrew Survival - STTR Topic DON26TZ01-NV014

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $240,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Develop a lightweight, compact, rugged, and reliable device that can convert seawater into safe, drinkable water. The device should minimize bulk and human energy expenditure, while maximizing output.

Description:

Survival in a life raft on the open ocean depends greatly on the availability of potable water. Naval aircrew currently carry prepackaged water in soft packets placed within the ejection seat survival kit and aircrew survival vest sufficient to sustain life for less than one day. Reverse osmosis desalinators and forward osmosis nutrient packs are commercially available to the recreational seafarer. However, neither of these approaches are designed to maximize the amount of drinkable water while minimizing the amount of human energy expended, while constrained by limited space within a survival kit. Manual Reverse Osmosis Desalinator (MROD) devices are labor intensive, requiring more than 2500 pumps to produce one liter of water in one hour. Such human powered devices may require more energy expenditure than the calories available to stranded aircrew. Forward osmosis products available for the recreational sailor can produce potable beverages with little manual effort, but the total output capacity for aircrew is limited by the storage volume of the ejection seat survival kit. Current options for supplying sufficient drinking water to sustain life throughout extended rescue durations are inadequate.

Innovative solutions will minimize or eliminate aircrew physical activity/exertion, while producing at least one gallon of drinkable water per day, with a minimum salt rejection of 95%. Concepts utilizing novel chemical processes or nanotechnology are preferred over simple refinements of current osmosis technology.

The device should:

a) fit within a Naval Aircraft Common Ejection Seat (NACES) survival kit (an envelope approximately 6½"x14½"x4½") along with an Emergency Oxygen System (EOS) and an LRU-38/P life raft, but not exceed 114 cubic inches.

b) operate in near freezing brine water/freshwater/saltwater.

c) operate in turbulent or calm water conditions.

d) operate reliably in cold and hot ambient air from -40° to +125°F (-40° to +51°C).

e) operate after exposure to temperature extremes from -65° to +160°F (-54° to +71°C).

f) operate after exposure to mold, mildew, flame, and salt fog.

g) not create hazards (i.e., burn, injury, Foreign Object Debris (FOD), snag/trip, and static discharge) in any mission or survival operations.

h) operate following a 600-knot seat ejection.

i) operate after repeated exposure to altitudes up to 70,000 ft (0.65 psi).

j) operate after exposure to typical fixed-wing ejection seat aircraft vibration levels, at frequencies from 5 Hz-2000 Hz).

k) provide resistance to environmental contaminants (i.e., sand, petroleum, oil, lubricants, and solar radiation).

l) not interfere with survival vest or mounted gear, armor/armor release, seat harnesses, helmets or head mounted gear.

m) be capable of operating after 15 months in a packed state (360-day inspection cycle plus 90 day shelf life) while exposed to temperature ranges of -65° to 160°F (-54° to +71°C).

n) weigh less than 2 lbs.

o) use Berry Amendment-compliant materials and manufacturing techniques.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

AI/ML Assisted Field Troubleshooting in Avionics Optical Network - SBIR Topic DON26BZ01-DV003

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $2 Million.

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Design, develop, and integrate a portable artificial intelligence/ machine learning (AI/ML)-enabled diagnostic module compatible with existing Optical Backscattering Reflectometer (OBR) and Optical Time Domain Reflectometer (OTDR) mainframes. The module will be engineered to support in-field optical network troubleshooting and management for high-speed communication systems.

Description:

Current airborne military (mil-aero) core avionics, electro-optical (EO), communications, and electronic warfare systems are experiencing continuous growth in bandwidth demand, coupled with stringent requirements to reduce Size, Weight, and Power (SWaP). Earlier-generation multimode optical fibers have replaced traditional shielded twisted-pair wire and coaxial cable, offering increased electromagnetic interference (EMI) immunity, higher bandwidth and throughput, and notable reductions in aircraft size and weight.

However, maintenance and troubleshooting of these advanced optical networks remain highly dependent on traditional telecommunication test equipment. Identifying and resolving faults—such as fiber breaks, fractures, and high-loss terminations—requires locating and distinguishing anomalies within meter-level precision, whereas modern avionic information-processing networks demand centimeter-level spatial resolution from source to detector.

Fault detection must extend beyond typical Weapons Replaceable Assembly (WRA) interfaces to identify:

Backplane/module degradation

Line replaceable module-to-optical transceiver faults

Polymer waveguide failures

Inline sensor (fiber grating) issues

Optical link loss across concatenated waveguide segments

Frequent airframe panel removal during fault isolation disrupts aircraft availability and mission readiness—especially for stealth platforms—highlighting the need for faster, more accurate, and less intrusive diagnostics.

To overcome these limitations, a portable AI/ML-enabled troubleshooting device is proposed to support field diagnostics across military airborne fiber-optic systems. The device will leverage next-generation reflectometry technologies and machine intelligence to enhance fault resolution precision and technician efficiency.

Key Capabilities:

AI-Augmented Fault DetectionReal-time identification of defects (breaks, voids, misalignments, link degradation)

Pattern recognition and anomaly classification using historical signature databases

AI-Driven Virtual AssistantsOn-device or network-connected chatbots providing guided maintenance workflows

Embedded AR interface for overlaying diagnostics on test hardware in real time

Advanced Troubleshooting MetricsSpatial resolution to centimeter scale across multiple fiber types

Predictive maintenance algorithms to reduce unplanned network downtime

Plug-and-Play Integration Fully compatible with existing portable OTDR/OBR mainframes

Support for both multimode (50/125, 62.5/125, 100/140 µm) and single mode (9/125 µm) fiber types

GUI developed for intuitive field use across all operational conditions

Wavelength and Environmental ResilienceOperational wavelength support: SWDM and CWDM

Designed for MIL-PRF-28800 Class 2 with select Class 1 enhancements

Operational temperature range: –40°C to +95°C

Resistant to mechanical shock, altitude variation, vibration, humidity, and thermal cycling

The device will build upon a fusion of legacy and emerging fiber-optic diagnostic technologies, including:

Optical Time Domain Reflectometry (OTDR)

Optical Backscatter Reflectometry (OBR)

Photon-Counting OTDR (PC-OTDR)

Low Correlation OTDR (LC-OTDR)

Pseudo Random Sequence (PRS) Correlation OTDR (C-OTDR)

Optical Frequency Domain Reflectometry (OFDR)

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

CDMRP: FY26 Epilepsy Research Program (ERP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Epilepsy Research Program (ERP) from the Congressionally Directed Medical Research Programs (CDMRP), managed by the Defense Health Agency Research and Development – Medical Research and Development Command, is expected to fund innovative research focused on post-traumatic epilepsy (PTE) and related comorbidities.

The program’s goal is to improve quality of life for Service Members, Veterans, caregivers, and the broader epilepsy community by advancing understanding of the biological mechanisms, epidemiology, progression, and treatment of PTE.

This announcement is a pre-announcement, meaning investigators should begin preparing ideas now. Application deadlines have not yet been released. The official Funding Opportunity Announcements (FOAs), which will include submission deadlines, will be posted on Grants.gov.

How much funding would I receive?

Funding amounts depend on the award mechanism.

• Idea Development Award

  • Maximum funding: $1 million total costs

  • Maximum period of performance: 3 years

• Leveraging Research Award

  • Maximum funding: $800,000 total costs

  • Maximum period of performance: 3 years

• Research Partnership Award

  • Maximum funding: $2 million total costs

  • Maximum period of performance: 3 years

• Virtual Post-Traumatic Epilepsy Research Center – Leadership Award

  • Maximum funding: $1.6 million total costs

  • Maximum period of performance: 4 years

• Virtual Post-Traumatic Epilepsy Research Center – Faculty Award

  • Maximum funding: $800,000 total costs

  • Maximum period of performance: 3 years

Total costs include direct and indirect costs.

What could I use the funding for?

ERP funding supports research designed to advance understanding of post-traumatic epilepsy (PTE) and related conditions. Applications should address at least one of the program’s focus areas:

Markers and Mechanisms of PTE

• Identification of biomarkers predicting epilepsy development

• Research into biological mechanisms that could prevent epileptogenesis or seizure activity

Epidemiological Characterization of PTE

• Identifying predictors of epilepsy development

• Studying patient outcomes such as latency to epilepsy onset, comorbidities, and mortality

• Measuring impacts on quality of life for patients and caregivers

Longitudinal Studies of PTE Progression

• Tracking disease progression over time

• Evaluating treatment outcomes and quality of care

• Studying interactions between epilepsy and comorbid conditions such as psychiatric disorders, cognitive deficits, sleep disorders, and fatigue

Innovative Research Tools and Technologies

• Artificial intelligence or bioinformatics tools

• Clinical databases and advanced device technologies for seizure detection and diagnosis

• Models for studying post-traumatic epilepsy

• Tools enabling future clinical trials

Are there any additional benefits I would receive?

Some award mechanisms provide benefits beyond funding.

For example:

• Research Partnership Award

  • Supports collaborative research between two named Principal Investigators

• Virtual Post-Traumatic Epilepsy Research Center – Leadership Award

  • Provides funding to lead a virtual research center

  • Includes responsibilities such as mentoring investigators and facilitating collaboration

• Virtual Post-Traumatic Epilepsy Research Center – Faculty Award

  • Supports early-career researchers or investigators new to the PTE field

  • Includes mentorship and career development within a collaborative research environment

What is the timeline to apply and when would I receive funding?

The process will include:

• Pre-application submission through eBRAP

• Pre-applications will be Letters of Intent

• Full applications will follow the requirements outlined in the final FOAs on Grants.gov

Where does this funding come from?

Funding comes from the FY26 Defense Appropriations Act, which provides funding for the Epilepsy Research Program (ERP).

The program is administered by:

• Congressionally Directed Medical Research Programs (CDMRP)

• Defense Health Agency Research and Development – Medical Research and Development Command

ERP focuses on research that benefits Service Members, Veterans, caregivers, and the broader epilepsy community.

Who is eligible to apply?

Eligibility depends on the award mechanism:

• Idea Development Award

  • Independent investigators at any career level may serve as Principal Investigator

• Leveraging Research Award

  • Independent investigators at any career level may serve as Principal Investigator

• Research Partnership Award

  • Two named Principal Investigators who are independent investigators at any career level

• Virtual P-TERC Leadership Award

  • Director and Deputy Director must be independent investigators with:

    • Strong history of PTE research funding

    • Peer-reviewed publications

    • Mentorship experience

• Virtual P-TERC Faculty Award

  • Early-career investigators or investigators new to the PTE field

What companies and projects are likely to win?

ERP prioritizes research that:

• Advances understanding of post-traumatic epilepsy and associated comorbidities

• Improves quality of life for Service Members, Veterans, and caregivers

• Demonstrates innovation or high creativity

• Challenges existing research paradigms

• Leverages existing datasets, cohorts, or research infrastructure

• Includes strong collaborations where appropriate

Are there any restrictions I should know about?

Key requirements include:

• Pre-applications must be submitted through eBRAP

• All pre-applications are Letters of Intent

• Full applications must follow the requirements of the final Funding Opportunity Announcements on Grants.gov

• Applications must align with the ERP’s focus areas on post-traumatic epilepsy

How long will it take me to prepare an application?

Preparation time will depend on the complexity of the project and research team.

Typical CDMRP submissions involve:

• A Letter of Intent (pre-application)

• A full application including research plan, budget, and supporting documentation

Because official deadlines have not yet been released, investigators should begin developing project concepts now so they are ready once the FOAs are posted.

How can BW&CO help?

BW&CO supports companies and research teams pursuing CDMRP and other federal research funding by:

• Identifying the most competitive award mechanism

• Developing a compelling proposal narrative aligned with program priorities

• Structuring the research plan and milestones

• Coordinating multi-institution collaborations

• Managing the full submission process through eBRAP and Grants.gov

Our team has extensive experience helping applicants pursue defense health and biomedical research funding.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: FY26 Alzheimer’s Research Program (AZRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Fiscal Year 2026 (FY26) Alzheimer’s Research Program (AZRP) is expected to release funding opportunities through the Congressionally Directed Medical Research Programs (CDMRP) to support impactful research addressing Alzheimer’s disease and Alzheimer’s disease–related dementias (AD/ADRD).

The program’s mission is to fund solution-oriented research that improves quality of life for people living with Alzheimer’s disease and related dementias, including Service Members, Veterans, their Families, and the general public.

Congress appropriated $15.0 million for the FY26 Alzheimer’s Research Program.

The FY26 AZRP is expected to support research that improves diagnosis, prevention, risk reduction, and quality of life for individuals affected by AD/ADRD.

How much funding would I receive?

Funding depends on the award mechanism.

Transforming Care Award

• Maximum funding: $1.6M total costs

• Maximum period of performance: 4 years

Career Initiation or Transition Partnership Option (CITPO):

• Maximum funding: $1.8M total costs

• Maximum period of performance: 4 years

Transforming Diagnosis Award

• Maximum funding: $1.5M total costs

• Maximum period of performance: 4 years

Career Initiation or Transition Partnership Option (CITPO):

• Maximum funding: $1.7M total costs

• Maximum period of performance: 4 years

Transforming Research Award

• Maximum funding: $1M total costs

• Maximum period of performance: 3 years

What could I use the funding for?

Funding supports non-incremental, solution-focused research addressing Alzheimer’s disease and related dementias (AD/ADRD).

The allowable research depends on the mechanism.

Transforming Care Award

Supports well-designed non-incremental clinical research or clinical trials in dementia care that provide solutions for individuals living with AD/ADRD.

Projects may address:

• Care interventions

• Strategies or technologies for dementia care

• Tools that improve daily living and support systems

• Approaches that reduce caregiver burden and stress

• Methods that improve quality of life for individuals with dementia

Applications are encouraged to prioritize both:

• Individuals living with AD/ADRD

• Their care partners

Transforming Diagnosis Award

Supports solutions-oriented research addressing barriers to diagnosis, disease monitoring, or prognosis.

Barriers may include:

• Diagnostic technologies

• Cost barriers

• Access to diagnostic tools

• Clinical implementation challenges

• Biomarker validation

• Disease monitoring methods

• Lack of longitudinal data for prediction or prognosis

Research may include:

• Prospective human subject recruitment

• De-identified human samples, specimens, or datasets

Transforming Research Award

Supports research that reduces risk and prevents the development of AD/ADRD.

Applications must address one of two focus areas:

Risk factor knowledge

• Identification or validation of risk or protective factors

• Environmental, epigenetic, genetic, lifestyle, or occupational risks

Risk reduction solutions

• Non-pharmacological methods

• Technologies

• Prevention strategies that reduce risk of AD/ADRD

The program encourages studies leveraging existing cohorts or datasets, including cohorts 65 years or younger.

Are there any additional benefits I would receive?

The pre-announcement does not specify additional non-funding benefits.

However, CDMRP programs typically provide:

• Access to a two-tier review system combining scientific peer review and programmatic review to ensure scientific merit and mission relevance.

• Opportunities to collaborate with researchers, clinicians, and community stakeholders affected by the disease.

What is the timeline to apply and when would I receive funding?

The pre-announcement states that:

• Pre-announcements are released first

• Funding Opportunity Announcements (FOAs) with full application details will follow.

Applications must comply with the final FOAs published on:

• CDMRP website

• Grants.gov

• eBRAP

Where does this funding come from?

This funding comes from the Congressionally Directed Medical Research Programs (CDMRP) within the Department of Defense.

Key facts:

• Funding was appropriated through the Consolidated Appropriations Act, 2026.

• CDMRP manages biomedical research programs supporting the health of Service Members, Veterans, their Families, and the American public.

Who is eligible to apply?

Detailed eligibility criteria will be provided in the official Funding Opportunity Announcements.

What companies and projects are likely to win?

The AZRP supports projects that:

• Address critical needs in Alzheimer’s disease and related dementias

• Deliver solution-oriented outcomes

• Improve diagnosis, prevention, or patient quality of life

• Demonstrate clear relevance to Service Members, Veterans, their Families, or the broader public

Projects that show strong scientific merit and mission relevance are prioritized through CDMRP’s two-tier review process.

Are there any restrictions I should know about?

Restrictions and requirements are not specified in the pre-announcement.

These details—including allowable costs, research scope limitations, and regulatory requirements—will be defined in the full Funding Opportunity Announcements.

How long will it take me to prepare an application?

The preparation timeline is not specified in the pre-announcement.

CDMRP programs often use a two-stage process that may include:

• Pre-application submission

• Invitation to submit a full application

However, the specific process for FY26 AZRP is not specified in the pre-announcement.

How can BW&CO help?

BW&CO supports teams pursuing CDMRP funding by:

• Assessing project fit with the AZRP mission and research priorities

• Developing a competitive technical narrative

• Structuring proposals to align with CDMRP review criteria

• Managing submission strategy, compliance, and timeline

• Coordinating collaborators, investigators, and supporting documentation

Our team has extensive experience supporting Department of Defense CDMRP grant applications.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: FY26 Autism Research Program

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Fiscal Year 2026 (FY26) Autism Research Program (ARP) from the Congressionally Directed Medical Research Programs (CDMRP) will fund innovative, high-impact research with clinical relevance that improves outcomes for individuals with autism and their families. The program released this pre-announcement to allow investigators time to plan proposals before the formal Funding Opportunity Announcements (FOAs) are released.

The FY26 ARP was funded through the FY26 Defense Appropriations Act. Investigators should begin preparing now because the program will require a pre-application before submission of a full proposal once the FOAs are released.

Application deadline: The deadline is not specified in the solicitation. Deadlines will be published in the FY26 ARP funding opportunity announcements when they are released on Grants.gov.

How much funding would I receive?

Funding depends on the specific award mechanism.

Career Development Award

• Maximum funding: $750,000 total costs

• Maximum period of performance: 3 years

Clinical Trial Award

• Maximum funding: $1.5 million total costs

• Maximum period of performance: 4 years

Clinical Trial Award – Nested Early-Career Investigator Option

• Maximum funding: $1.75 million total costs

• Maximum period of performance: 4 years

Idea Development Award

• Maximum funding: $750,000 total costs

• Maximum period of performance: 3 years

Total costs include direct and indirect costs.

What could I use the funding for?

Each mechanism supports different types of autism research.

Career Development Award

• Supports early-career independent investigators or established investigators transitioning into autism research.

• Projects must pursue research with the potential to have a major impact on autism.

• Supported activities include:

  • Innovative, high-impact research ideas

  • Early-phase, proof-of-principle clinical trials

• Preliminary data is required.

Clinical Trial Award

• Supports research with the potential to have a major impact on the treatment and/or management of autism.

• Projects must involve clinical trials supported by preliminary data.

Clinical Trial Award – Nested Early-Career Investigator Option

• Allows a senior investigator (initiating PI) to collaborate with a young investigator.

• Supports the development of investigators pursuing careers in autism clinical trial research.

Idea Development Award

• Supports innovative, high-impact ideas that advance understanding of autism and lead to improved outcomes.

• Includes a Partnering PI Option allowing collaboration between two investigators.

• Clinical trials are not allowed under this mechanism.

All mechanisms require preliminary data relevant to the proposed project.

Are there any additional benefits I would receive?

The program includes several structural benefits:

• Career Development Award supports the transition of researchers into the autism field.

• Clinical Trial Award – Nested Early-Career Investigator Option provides structured development for young investigators.

• Idea Development Award – Partnering PI Option encourages collaboration between investigators.

These structures are designed to expand the autism research workforce and accelerate impactful research.

What is the timeline to apply and when would I receive funding?

• Pre-announcement released: March 2, 2026

• Funding Opportunity Announcements (FOAs) will be posted on Grants.gov.

• Pre-application submission through eBRAP is required before submitting a full application.

• Application submission is by invitation only after review of the pre-application.

• Pre-application and full application deadlines are not specified in the pre-announcement.

• Funding start dates are not specified in the pre-announcement.

Where does this funding come from?

Funding for the program comes from the FY26 Defense Appropriations Act and is administered by the Congressionally Directed Medical Research Programs (CDMRP) within the Defense Health Agency Research and Development – Medical Research and Development Command.

The program is part of the Department of Defense’s Autism Research Program (ARP).

Who is eligible to apply?

Eligibility varies by mechanism.

Career Development Award
Applicants must:

• Be independent investigators at or below the level of Assistant Professor, or equivalent,

  or

• Be established investigators in a field other than autism at or above the level of Assistant Professor seeking to transition into autism research.

Additional requirements:

• Must not have previously received a Career Development Award (or equivalent) from any CDMRP program or other federal agency.

• Must not have received more than $250,000 in total direct costs for previous or concurrent autism research as a PI of federally or privately funded non-mentored peer-reviewed grants.

• Must hold a Ph.D., M.D., M.D./Ph.D., or equivalent at the time of pre-application submission.

• Must not be a graduate student, postdoctoral fellow, or other mentored researcher.

Clinical Trial Award

• Independent investigators at any career level.

Clinical Trial Award – Nested Early-Career Investigator Option
Young investigator must:

• Be currently in postdoctoral training or have completed postdoctoral training.

• Be no more than 7 years from receipt of a terminal degree.

• Commit at least 50% time to the project.

Idea Development Award

• Independent investigators at any career level.

What companies and projects are likely to win?

Based on the pre-announcement, competitive applications will likely:

• Propose innovative, high-impact research addressing autism

• Demonstrate strong preliminary data

• Show potential for major impact on understanding, treatment, or management of autism

• Align with the goals of the specific award mechanism

• For collaboration options, demonstrate meaningful partnerships between investigators

Applications must clearly demonstrate scientific merit and potential impact.

Are there any restrictions I should know about?

Key restrictions include:

• Pre-application submission through eBRAP is required before submitting a full application.

• Full applications are submitted by invitation only.

• Preliminary data is required for all mechanisms.

• Idea Development Award applications cannot support clinical trials, including a clinical trial aim.

• Career Development Award applicants must meet prior funding and career stage restrictions.

All applications must conform to the final Funding Opportunity Announcements posted on Grants.gov.

How long will it take me to prepare an application?

The solicitation does not specify preparation time.

However, because the ARP uses a two-stage process (pre-application followed by invitation-only full application), applicants typically need time to:

• Prepare a competitive pre-proposal

• Develop preliminary data and a detailed research plan

• Assemble collaborators and institutional approvals

Investigators are encouraged to begin planning early before FOAs are released.

How can BW&CO help?

BW&CO can support applicants throughout the ARP application process, including:

• Evaluating project fit with ARP mechanisms

• Developing a competitive proposal strategy

• Structuring impact-focused research narratives

• Managing the pre-application and full application process

• Preparing supporting documents and compliance materials

• Coordinating multi-investigator collaborations

Our team has extensive experience supporting Department of Defense CDMRP grant applications.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

Flexible Printed Thermoelectric Cooling Film - STTR Topic DON26TZ01-NV013

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $240,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Develop a low-cost and lightweight thermoelectric cooling film that could be used to cool the warfighter (small scale) or surfaces on military platforms (larger scale) using printed organic semiconductors. The flexible cooling films should have a bending radius of less than one inch to easily wrap around pipes, wrists, and ankles, and be able to conform to complex curvatures on larger surfaces.

Description:

Thermoelectric cooling devices based on narrow bandgap semiconductors such as bismuth telluride are commercially available. They are solid state devices and thus do not have the large footprint and moving parts associated with vapor compression refrigeration systems; however, they operate with lower efficiency. They are well-suited for cooling small flat surfaces where one is more concerned with the form factor than efficiency. For many practical applications, these square ceramic tile thermoelectric devices are heavy and too rigid, and do not offer conformal contact to curved surfaces.

Over the past fifteen years, a lot of progress has been made on organic thermoelectric materials. Though the thermoelectric figure of merit (ZT) has not caught up to that of bismuth telluride and other inorganic materials, the potential to make low-cost, lightweight, and flexible devices has opened a new application space for thermoelectric cooling where flexibility and large-area conformal contact are prioritized over efficiency. For instance, lightweight headbands and wristbands only need to remove a small amount of heat to provide significant cooling sensation to the user. Likewise, there are diffuse, large surface area applications with similar cooling needs. Prior research was summarized in a recent review article by Segalman [Ref 1].

The conducting polymer Poly(3,4-ethylenedioxythiophene) [PEDOT] was identified as a strong candidate for the p-type leg in the p-n device, but device performance has been limited by the lack of suitable n-type materials. The organic electronics community has long wrestled with n-type materials due to potential oxidation of the electron carriers. A number of inherently stable and high performing n-type polymers have recently been developed [Ref 2] that should complement the available p-type materials and enable significantly improved thermoelectric cooling device performance. New device designs obtainable with simple fabrication must be developed to take advantage of the anisotropic thermal conductance and charge transport in these materials, which is typically maximized in-plane and along the polymer molecular backbones, such that measured thin film behaviors successfully translate into device performance. A number of design and fabrication strategies have been demonstrated but much more innovation is possible [Ref 1]. It is an appropriate time to develop lightweight, flexible thermoelectric cooling devices for these niche applications.

This STTR topic is for low-cost, lightweight, and flexible thermoelectrics for personal cooling as well as for large area applications.

The flexible cooling films should have a bending radius of less than one inch to easily wrap around pipes, wrists, and ankles, and be able to conform to complex curvatures on larger surfaces. The stated applications are near-ambient temperatures though the conjugated polymers should be able to handle temperatures up to 200°C. Composite approaches that are appropriate are welcome. This topic is not soliciting a fabric-based solution.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Broadening Availability of Regimens for K-9s (BARK) - Open Topic - SBIR Topic DPA26BZ01-NP001

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $250,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Develop medical products that are interoperable and compatible across humans and dogs to meet the health needs of both human warfighters and military working dogs.

Description:

Military working dogs (MWDs) are critical to national security, serving as force multipliers by enhancing the lethality and survivability of their teams through their unique senses, agility, and autonomy. Providing effective medical care for MWDs is critical but imposes significant challenges. Not all human medical products work for canines (K-9s), who sometimes require separate, specialized veterinary products. MWD handlers must therefore carry extra medical equipment to provide emergency care for their K-9 partner, exacerbating equipment loads and impeding operational capacity. Specialized equipment also expands medical materiel requirements and dependence on the less-resourced veterinary market, encumbering acquisition and sustainment activities.

Medical technologies that are interoperable and compatible across humans and dogs can address unmet needs of valuable MWDs while lessening the burden on medics, logisticians, and other contributors to force health protection. Species-interoperable medical technologies, particularly those supporting acute and tactical care, will improve lifesaving medical care for these MWDs while mitigating logistical and operational burdens of treating both human and K-9 warfighters.

The Defense Advanced Research Projects Agency (DARPA) is soliciting medical technologies that are interoperable and compatible across humans and dogs. Technologies of greatest interest allow for the replacement of existing products in medical sets with interoperable products, reducing the total amount of medical supplies—expanding capability without expanding the kits. Examples of specific technologies of interest include, but are not limited to:

Filters for donor plasma capable of removing cross-reactive antigens that impede compatibility across species;

Universal synthetic plasma designed with all necessary functional components for transfusion;

Sensors and form-factors that enable physiological monitoring (e.g., core body temperature and blood pressure) or triage in both humans and dogs;

Medical devices (e.g., splints, backboards, tourniquets, mechanical ventilators) designed to be rapidly adjustable at point of care for flexible use across anatomies;

Interoperable medical countermeasures (MCMs) and form-agnostic personal protective equipment to mitigate or protect against chemical, biological, radiological, and nuclear threats; and

Delivery mechanisms that can modulate dosing, including through excipients or combination devices (e.g., autoinjectors), to enable universal use of pharmaceuticals and MCMs.

The aim of the solicitation is to create a demonstrative prototype that can quickly progress to pre-clinical or clinical testing during a contracted SBIR Phase II period of performance (PoP). Research that merely tests existing products, including collection of data to titrate dosages or support label expansion of a marketed product to an additional species, is unlikely to achieve the degree of technical innovation a successful proposal should demonstrate. New drug discovery is discouraged but may be considered in particularly compelling cases. Products enabled by proposed research should feasibly be safe and effective in both humans and canines—to be verified in future trials—for use cases where no single existing product serves both patient sets. Technologies of interest should be capable of achieving substantially equivalent or superior performance in humans compared to currently approved options.

An initial white paper describing the technical approach is required and will be evaluated. If DARPA selects a white paper for further evaluation, the Government will issue an invitation to submit a full proposal. The technical white paper should include an overview of the proposed concept with details to support feasibility. The overview should address the bullets below, which are listed in order of importance:

Proposed concept: Describe the proposed research and medical product. Outline the design and operation of the main components that are being proposed for development and mode(s) of action. Use clear calculations, preliminary data, or mechanistic justifications to support feasibility of the proposed concept.

Concept of employment: Identify how the proposed product could be employed. Provide details on the intended use, indication, and effect, and the prevalence and impact of the addressed medical condition. What benefits, including new capabilities or improved metrics, does the proposed solution provide compared to current commercial off-the-shelf (COTS) options (e.g., commercially available human- or canine-specific products)?

Path to market: Identify relevant predicate or otherwise established products that have been approved, licensed, authorized, or cleared by the U.S. Food and Drug Administration (FDA) or other relevant regulatory authority. Provide a general plan or strategy for securing market access and ensuring regulatory compliance for both humans and canines if the proposed technology is successful and shown to be safe and effective. For any special FDA programs noted (e.g., Breakthrough Device designation, 513(g)), ensure that the white paper describes how the medical product meets the program requirements.

Scalability: Provide a brief analysis of the feasibility of scaling the technology across both the DoW and industry. Are the achievable production costs low enough to merit widespread adoption, especially if alternative human- or canine-specific products are available? Is the system sufficiently familiar or intuitive to medics, handlers, and clinicians that large-scale deployment and administration wouldn’t require significant training or modification of protocols? What are the projected maintenance and storage requirements, operational availabilities, and service lifetimes, and, if applicable, how do they compare with COTS alternatives?

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Advanced Damage Criticality Analysis - SBIR Topic DON26BZ01-DV005

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $2 Million.

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Develop a passive Structural Health Monitoring (SHM) system to identify, locate, and characterize the severity of defects and cracks due to fatigue loading or impacts based on novel or advanced technologies with a basis in physics and avoiding qualitative assumptions.

Description:

The Navy seeks an effective passive Structural Health Monitoring (SHM) system for Navy ship hulls and other structures that can monitor defects, such as crack growth from fatigue or impacts, and provide actionable information about the severity of the defect in an automated manner, i.e., in real time. Such fatigue cracks develop and grow in Navy ship hull welds and plating from cyclical life-cycle stresses and event-driven forces from severe sea states, collisions, and groundings.

The U.S. Navy and other navies around the world have installed SHM systems to monitor hull structural health but almost all are based on using strain gauges to monitor stresses on the hull and inferring crack growth based on fatigue life calculations. For example, the Military Sealift Command (MSC) has worked with the American Bureau of Shipping (ABS) and installed SHM systems consisting of strain gauges and accelerometers on several ships in the T-EPF class, which monitor hull deflection and dynamic movement due to the ship’s loading and the sea states encountered. The data from these sensors is being fed into a digital twin model developed to calculate structural stresses for managing vessel survivability and to minimize operating risk.

There have been some attempts to develop fiber optics sensors to measure strain or Acoustic Emission (AE) sensors to monitor fatigue cracks directly. These approaches have seen varying levels of success, yet, better systems are needed. There may even be some applications for LiDAR use to improve success probability. The Navy is particularly interested in locating and characterizing the severity or criticality of a defect if one is detected. Currently there is not a system available on the commercial market.

The Navy’s need for such hull monitoring capability has become more important with the introduction of high-speed and catamaran vessels, which are more prone to hull cracking due to the designs of the ships, materials of the hull, and stresses experienced in high seas. An ideal system would be capable of monitoring large areas of the ship’s hull with sensing devices that provide cost effective coverage with the following capabilities:

Detect and identify the location of crack growth signals in the hull if they exist in the presence of ship’s background noise without producing false positives or negatives.

Produce results in an automated manner, i.e., real time, so they are immediately available to the operating crew.

Provide insight as to the severity of the crack growth considering the complex geometries found in hull structures with varying thicknesses and stiffeners.

The Navy would benefit from understanding structural risks in real time with the goal of minimizing the possibility of incurring structural damage at sea. The SHM system the Navy needs should provide meaningful information on ship structural health and reduce inspection and maintenance costs during repair availabilities by identifying areas of concern or damage in advance.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Synthetic Alkali Atom Vapor Density for Atom-Based Sensors - SBIR Topic DON26BZ01-NV037

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $240,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Simplify the thermal management of practical atom-based quantum sensors based on alkali atoms by creating a passive atom source operated at thermal equilibrium based on a synthetic alkali vapor density for rubidium or cesium atoms.

Description:

Quantum sensors based on atoms offer the opportunity to produce measurements with excellent sensitivity or long-term stability, making them attractive use in atomic clocks, magnetometers, or inertial sensors. In these sensors, the atomic vapor represents the sensing media where variations in signal magnitude from fluctuations in atom number can lead to instability or loss of sensitivity. Maintaining consistent signal throughout environmental conditions represents one of several key design criteria for atom-based sensors for use outside the laboratory.

Many atom-based sensors rely on heavy alkali atoms, specifically rubidium and cesium. This is because of the simplified, hydrogen-like energy level structure, the availability of narrow-linewidth semiconductor diode lasers on the relevant D1 (795/895 nm) and D2 (780/852 nm) transitions, the accessibility of commercial microwave electronics at the 3-10 GHz hyperfine splittings, and the ease of production of vapor phase atoms at modest temperatures. The temperature dependence of the alkalis [Ref 1] leads to thermal stabilization at 80-130°C (ideal for vapor cells at 10e12-10e14/cc) or closer to room temperature (ideal for atom trapping at 10e8-10e10/cc). These temperatures rarely align with thermal profiles of other aspects of the system, requiring additional design at the expense of size, weight, and power (SWaP).

Active approaches to alkali regulation have been demonstrated to manipulate the vapor to a non-equilibrium state. These approaches involve forced chemical reactions, intercalated graphite, alkali impregnated materials glasses [Refs 2,3]. In each case, a feedback loop must respond to measurements of the vapor density, leading to extra sensor complexity.

An equilibrium vapor density represents the simplest atom source which can be synthetically adjusted to an elevated temperature through a mixture [Ref 4]. Here, a primary species mixed with a secondary species reduces the equilibrium vapor density of both species by the mixing ratio following Raoult’s Law [Ref 5]. Selecting a lower vapor density secondary species limits the negative impact of additional atom-atom collisions. Such an approach can be applied to laser-cooled systems in addition to vapor cells to enable equilibrium operation at elevated system temperature, providing tight thermal regulation at low power.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Applied Neuroanalytics for Optimization of Naval Training and Operational Readiness - SBIR Topic DON26BZ01-NV033

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $240,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Develop and demonstrate a neuro-enhanced artificial intelligence (AI) system that captures, analyzes, and operationalizes neurophysiological and behavioral data to provide near real-time, adaptive feedback for improved training efficiency, performance, and operational readiness of U.S. Navy personnel.

Description:

The U.S. Navy Force Design 2045 (CNO NavPlan 2024) highlights the importance of the warfighter and human-machine teaming in the future fight, emphasizing the criticality of developing high-performing teams and leaders that are resilient, adaptable, and warrior tough while supporting an increasingly hybrid Fleet of manned assets augmented with thousands of unmanned assets. The future fight will likely require operators to 1) digest and synthesize large amounts of data from an extensive network of humans and machines, 2) make decisions more rapidly due to advances in AI, enhanced connectivity, and autonomous weaponry and 3) oversee a greater number and types of robotics, including swarms (RAND, 2024).

Critical features of this paradigm shift towards manned-unmanned teaming and emphasis on improving warfighter performance are how we train operators. Training is at the forefront of the modernization of Naval operations to enhance readiness and lethality, and this will depend heavily on the cognitive resilience and decision-making capacity of warfighters in these novel, high-stress environments. Traditional training paradigms typically neglect real-time measurement and integration of cognitive and physiological performance states (e.g., mental effort, task engagement, lapses and slips of attention, complacency, mental fatigue, and stress). Emerging technologies for advanced data analytics grounded in neuroscience provide new capability that can enhance warfighter development and mission success by embedding neurofeedback into live and synthetic Naval training environments, providing novel analytical features and data to adapt training in near-real time and accelerate learning at the point of need.

The U.S. Navy seeks to identify a major step forward in neuro-enhanced AI systems to reduce time-to-proficiency and predict Sailor readiness within the unique maritime military environment. This envisioned capability will leverage and further develop Commercial Off-the-Shelf (COTS) neurotechnologies along with complimentary biosensors (e.g., electrocardiography [ECG], electromyography [EMG], eye tracking) and behavioral monitoring tools for Navy-specific use cases to interface with personnel, enabling adaptive and responsive system interaction based on near real-time human state data.

This SBIR topic will prioritize two key demonstrated factors in support of its objective: (1) the ability to collect neural, physiological, and behavioral data in parallel with operators using a desktop or higher fidelity simulator; and (2) the ability to analyze and interact with that data, both in near real-time and post-hoc, using an advanced language-understanding system coupled with an extensive foundational model of the human psychophysiology and/or behavior to provide feedback. This effort will complement existing Navy initiatives, such as those led by NAVAIR, NAWCAD, and NAWCTSD, enhancing existing learning environments through the addition of a brain-based performance layer.

The platform will deliver an autonomous solution for near real-time feedback, improved after-action reporting, and guided adaptation of training scenarios via open data standards that can be used to improve understanding of Sailor state (static and dynamic), which will be imperative for improving warfighter performance and training towards an ever-evolving mission in the future fight.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Bridge Environmental Light Pollution Mitigation and Control - SBIR Topic DON26BZ01-NV017

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $240,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Develop and deploy a safe, sustainable technology suited for controlling light pollution, thereby reducing ambient light levels across a bridge environment and providing adequate situational task lighting at select workstations across the bridge.

Description:

The Navy seeks a light mitigation technology for adequate situational lighting compliant with the Bridge Light Pollution Mitigation and Control Program (BLPM & CP). A comprehensive review of collisions involving U.S. Navy ships cited bridge lighting conditions as a possible contributing factor, stating the need to adhere to military standards for light producing displays and equipment installed on the bridges of surface combatant ships. The principal BLPM & CP’s objective is to resolve non-compliance of current bridge equipment and hardware with Military Standard MIL-STD-1472H, DOW Design Criteria Standard for Human Engineering [Ref 2]. Existing hardware often fails to satisfy requirements as outlined in the referenced standard (MIL-STD-1472H).

Light pollution mitigation efforts are necessary for all light producing technology installed on surface ship bridges/pilot houses. Reducing the undesirable effects of excessive or poorly designed lighting (i.e., light pollution) on night vision and bridge-watch stander performance will create greater situational awareness for crew members in a darkened bridge environment, therefore enhancing ship safety at sea.

The Navy seeks light mitigation technology for the bridge environment that complies with MIL-STD-1472H and enhances the effectiveness of all lights (e.g., screens, indicator lights, LED) during dark operations. This solution must also include a ruggedized work light that complies with free translation in three-dimensional space and free rotation on all three axes of rotation. There is currently no commercial technology that can meet this need.

The light should comply with all surface ship environmental standards regarding Electromagnetic Environmental Effects (E3), shock, vibration, and power quality and be able to produce light at the levels described in MIL-STD-1772H. The work light shall allow bridge watch standers to observe printed material at nighttime while still preserving night vision. A shipboard bridge work light must provide a focused beam of light with minimal glare, must be adjustable to direct light precisely where needed, and must offer the ability to control brightness levels with a cool color temperature to minimize eye strain while performing detailed tasks like reading or writing notes especially for crew members in a darkened bridge environment.

This scope of this effort includes all light emitting devices on the bridge, and is not limited to the following bridge systems:

Navigation Radar

Surface Search Radar

Situational Awareness Radar

Electronic Charting System

Ship Control Consoles

Voyage Data Recorder

Bridge-to-bridge Radio

Hull, Mechanical, and Electrical (HM&E) Systems

Damage Control Equipment/Displays

Command, Control, Communications, Computers, and Intelligence (C4I) Systems

Desired light mitigation solution parameters include but are not limited to:

Overlay applications, easily applied to existing displays, requiring no special tools, equipment, hardware, fixtures, adhesives, tapes, or fasteners.

Collapsible, foldable, stackable, and/or portable solutions to allow effective and easy storage when not in use.

Various optical densities and sizes of Neutral Density filter material may be overlaid on displays.

Solutions shall allow operator adjustment during application or installation.

Temporary covers, fixtures, filters, shades, etcetera must not alter the original design characteristics nor interfere with normal operation of mitigated light emitting sources.

Technology should not require external electrical power nor include additional electronic control systems or require any form of computer network connections.

Solution shall not leave any adhesive residue behind on surfaces after removal.

Mitigations may also include other formed caps to cover various instrumentations to reduce or eliminate light pollution associated with installed bridge equipment and other environmental light polluters.

Solution must be able to withstand extreme environmental conditions (e.g., high humidity, persistent vibration, temperature below 40° degrees Fahrenheit, etc.).

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Nudging Behaviors for Better Sleep - STTR Topic DON26TZ01-NV016

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $240,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Develop software for personalized and adaptive behavioral interventions (i.e., nudges) using commercial off-the-shelf (COTS) wearable hardware devices to promote and improve sleep outcomes and human performance in dynamic environments.

Description:

Despite extensive research on the mechanisms of sleep and behavioral modifications to improve sleep, relatively little is known about how context-sensitive behavioral nudging systems—those that dynamically suggest small, adaptive changes based on real-time data—can improve sleep quality and overall performance outcomes in complex, high-stakes settings. Fatigue caused by inadequate sleep negatively affects service members' performance and has contributed to accidents—resulting in deaths and hundreds of millions of dollars in damage to ships, vehicles, and aircraft [Ref 1]. “Nudging” refers to subtle interventions that steer behavior without restricting choices [Ref 2]. For example, non-obvious changes in how options are presented (e.g., ordering, timing, framing) have been shown to significantly affect sleep behaviors and dietary choices [Ref 3]. Recent advances in wearable sensor technology (e.g., smartwatches, rings, sleep trackers, etc.) allow for continuous collection of physiological and behavioral data. Many hardware devices are coupled with software that provide notifications, advice, and suggestions, but these are often canned, static statements that are simply pushed to the user (i.e., a one-way notification) and are not personalized to the user and/or their data.

Delivering adaptive behavioral nudges that learn and track the user’s state and responses, evolve over time, and promote sustained positive behavior change is also critical for mitigating the impact of sleep on operations. The objective of this STTR topic is to develop personalized and adaptive behavioral interventions (i.e., nudges) using COTS wearable devices to promote and improve sleep outcomes and human performance in dynamic environments. Achieving this objective requires: (1) research into integrated theoretical frameworks for personalized behavior change, grounded in cognitive, physiological, and contextual variables, and informed by mathematical tools such as dynamical systems modeling; (2) the development of adaptive algorithms that leverage Machine Learning (ML) and Artificial Intelligence (AI) to integrate with existing wearable and embedded sensors to identify optimal timing, modality, and content for real-time, minimally-intrusive, adherence-supporting behavioral nudges across diverse user states and operational contexts; (3) the exploration of human-centered communication strategies for delivering behavioral insights and recommendations, ensuring interventions are not only well-timed but also subtle and capable of supporting an ongoing user-system relationship built on trust and voluntary engagement; and (4) empirical testing in ecologically valid environments, including experiments that collect sleep and performance metrics to evaluate effectiveness, generalizability, and long-term behavioral impact.

Equal emphasis will be placed on (1) advancing theoretical models of behavior change, sleep regulation, and performance adaptation and (2) developing AI/ML systems and communication strategies for delivering behavioral nudges.

This topic focuses on sleep behavior due to its broad applicability to the general population, its foundational role in human performance, and the relative ease and reliability of measurement. Proposed efforts should aim to develop generalizable algorithms that integrate complex mathematical modeling and ML with cognitive-behavioral theory to drive adaptive behavioral interventions. These interventions must be compatible with existing wearable and embedded sensor ecosystems – this topic explicitly does not aim to develop new hardware, but instead to maximize the utility of currently available commercial sensors as inputs to a personalized, adaptive nudging system.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Advancing Human Modeling Tools for Enhanced Performance and Survivability in Austere Environments - STTR Topic DON26TZ01-NV015

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $240,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Develop an advanced suite of parametric human modeling tools incorporating USN/USMC aircrew anthropometric databases, empirical posture data, and 3D scans.

Description:

The goal of this STTR topic is to leverage newly available data and advances in digital human modeling to improve modeling fidelity for USN/USMC and other DOW aircrew to improve acquisition outcomes. Resulting improvements to operational and environmentally appropriate protective clothing and equipment size, design, and tariffing (i.e., determination of how much of each size needs to be procured and distributed) will yield significant benefits to Fleet readiness and sustainment, safety, performance, protection, and affordability.

Digital Human Modeling (DHM) applications and tools are used to design and assess items for the DOW including protective clothing, footwear, body armor, flight equipment (e.g., helmets, oxygen masks, survival vests, G-suits, torso harnesses, etc.), seating, restraint systems, workstations, cockpits, controls, ground vehicles, and much more. Using this technology early in the product lifecycle is essential to reducing development cost and schedule and informing design tradeoff decisions. Historically, use of DHM has been subject to a variety of limitations that affect model fidelity, which is how well the model represents reality. These limitations result in reduced utility of the technology when the limitations are understood, but more concerning are the potential adverse outcomes where the limitations have either not been understood or have been ignored. This is concerning for all types of design applications, but especially problematic in aviation where safety of flight is crucial. There is an abundance of feedback from aircrew regarding poor fit or lack of availability of the sizes of protective clothing and operational equipment they need. They experience pain and injury, reducing performance and impacting readiness. There is now the potential to exponentially improve DHM capabilities due to a variety of advances in 3D scanning, model development, and availability of aircrew population specific anthropometric data and empirical posture data representing real-world conditions for military aircrew.

Limitations to current DHM capabilities related to the users include issues with intuitiveness of the tools, the degree of expertise required for effective use, and the significant amount of time it takes to develop expertise. There is a shortage of expert users in both the DOW and industry. Manikins used in DHM analysis are commonly selected from built-in software libraries with inappropriate anthropometric measurements for the population and/or design being evaluated. DHM users with a poor understanding of anthropometry often fail to consider the multivariate nature of anthropometric accommodation ignoring the need to consider more than one measurement at a time and neglecting the critical interactions of the measurements. Users positioning/posturing manikins routinely use guesswork in the absence of empirical data to account for clothing and flight equipment, restraint systems, cushion compression, flesh compression, and postural variation. They often have a limited understanding of aircrew operations and/or environment leading to incorrect assumptions when setting up their models.

For some DHMs the anthropometric measurements that can be adjusted are not the ones that matter for design application and the underlying anthropometric data used in the application may not represent the target population. Multivariate use cases have been developed and in use on DOW aircraft acquisition programs since the mid-90s [Ref 1], but manikins representing the use cases are often not included in DHM manikin libraries causing users to default to inappropriate use of the manikins that are available. Until recently, the only USN/USMC aircrew anthropometric data available was from a 1960s database that did not include women. Currently, there are no DHM applications that include USN/USMC aircrew anthropometric data or associated multivariate use cases.

Another important consideration is that the commercially available DHM applications allow for analysis of one or more manikins, to include a family of multivariate use cases, but do not allow for parametric modeling of an entire population needed to accurately quantify the accommodation levels of a design.

The NAWCAD Human Systems Engineering Department has recently completed an aircrew/aviator anthropometric survey and is also collaborating with the USAF on the Seat Specific Posture Model (SSPM) Project to collect empirical posture data to improve modeling fidelity. This project was initially intended for the purpose of developing an aviation specific postural analysis tool in the RAMSIS DHM but will be useful for other applications as well. One example that this STTR topic proposes is that this aircrew data be used in in the development of aviation-specific parametric accommodation models. The US Army has successfully developed this type of modeling tool for ground vehicles with a great many advantages to their acquisition programs and alleviation of many of the limitations documented above [Refs 2,3,4].

There have also been significant advances to head, hand, and body models that can be leveraged to greatly improve DHM state of the art and acquisition outcomes [Refs 5-11]. Integration of aircrew-specific anthropometric and 3D scan databases would ensure modeling efforts reflect the intended population. Aviators are a distinctly different population and appropriate representation of them in modeling applications is essential. Model input parameters can be adjusted to represent the goals of the modeling effort (i.e., desired accommodation levels and target population or subpopulation) with adjustable demographic variables such as sex, age, and race/ethnicity. Modeling tools can incorporate the ability to consider not only traditional 2D anthropometric measurements, but 3D shape and/or non-traditional measurements with the goal of improving size design and fit prediction [Refs 12, 13]. Through new and affordable 3D body scanning technologies [Refs 14,15], it is possible for an individual’s specific anthropometry as well as their feedback on fit and preferred size to be run through an artificial intelligence (AI) algorithm to allow for ongoing improvements in size design, fit prediction, and tariffing. There have been advances in the development of head models that do not include hair artifacts [Ref 16], an important consideration in design. Improvements of head and hand models for dynamic or functional fit can improve the ability to digitally evaluate if masks maintain a seal when pilots talk or change facial expression and if gloves are designed appropriately for all pilot tasks, not just one static hand position. Posable manikins representing intended individuals or populations (multivariate use cases) can be easily customized and imported into any CAD environment or DHM software application for a variety of uses.

It is important to note that the proposed tools are meant to be supplemental not duplicative of other modeling tools currently available or in development. Having these proposed modeling tools be interoperable or integrated with existing or emerging tools is highly desirable. What makes these tools unique from existing/emerging modeling tools:

Inclusion of USN/USMC aircrew anthropometric databases and 3D scans.

Inclusion of SSPM project aircrew posture and reach data.

Solution is not computationally and/or time prohibitive to use.

Fills a gap in providing a solution that does not require an artisan modeler to make use of the models (easy to learn, simple user interface).

Leveraging existing models/methods for expeditious transition.

Models to be exported in common file formats to be interoperable with a broad range of CAD/DHM applications. No specific software applications are required.

Not strictly PPE focused but also applicable to clothing design.

Includes accommodation modeling tool for aircraft cockpits and workstations.

Will represent digital twins of individuals like other modeling tools, but will also provide population virtual assessment of fit, size design, tariffing recommendations, and report population accommodation levels.

Will allow for principal component analysis on a population and representation of boundary cases customized for specific applications.

Includes ability to import anthropometric data for a group of participants and create bivariate plots for visual comparison to aircrew population data.

Models will be web-hosted and freely/easily available to DOW civilians and contractors.

Intention is to have web-hosted instructional materials, user forum, document library, and subject matter expert information to encourage best practices and collaboration.

Framework will be built in to allow import of other population databases so other military populations including foreign military partners can be represented.

The proposed suite of tools would need to be easy to use, affordable, and easily accessed (e.g., hosted webapps and/or downloadable standalone applications) to facilitate practitioner usage and standardization. Accompanying guidance in the form of teaching materials, a user forum, links to relevant papers and reports, and a registry for subject matter experts and facilities wishing to be listed would be beneficial inclusions. The ability to create visualizations should also be considered. Allowing the import of anthropometry in a .CSV file for overlay with existing anthropometric databases in the form of bivariate plots of key anthropometric measurements is extremely helpful for population comparisons as well as confirming that human participants used for physical assessments adequately represent the target population. This proposed effort also seeks to put a framework in place that will allow incorporation of data from other populations and use of the models for other applications and users to include the entire DOW, foreign military partners, NASA, industry, and academia.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Development of Wearable Device for Detecting Biomarkers and Treating Viral and Bacterial Infections - SBIR DHA26BZ01-NV004

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $250,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Develop a non-invasive wearable device that can discretely detect biomarkers for and provide initial broad-spectrum treatment for pan-viral and pan-bacterial infections. If fielded for military use, it may require additional security measures.

Description:

The DHA Strategic Research Plan (SRP): Environmental Exposures (June 2024) lists two capability requirements under the “Assess” and “Treat” capability areas that align with this proposal: Environmental Detection and Health Risk Assessments under Assess and Environmental Exposures Treatment under Treat. In addition, the DHA SRP: Military Infectious Diseases (May 2024) lists three capability requirements under the “Prevent”, “Treat”, and “Enable” capability areas that align with this proposal: Prevention of Military Relevant Endemic and Emerging Infectious Diseases under Prevent, Treatment of Military Relevant Endemic and Emerging Infectious Diseases under Treat, and Core Competencies under Enable.

The Department of the Air Force (DAF) is looking for an advanced, non-invasive (does not break the skin or physically enter the body) wearable device (i.e., flash/continuous glucose style monitoring) capable of qualitatively detecting all-viral and all-bacterial infections using discrete biomarkers for such infections: TRAIL, MxA, CD46, IP-10, PTX3, or other non-blood based biomarkers (saliva, sweat, etc.) for viral infections and CRP, PCT, IL-6, IL-8, CD35, CD55, CD64, pro-ADM, or other non-blood based biomarkers (saliva, sweat, etc.) for bacterial infections. The end goal is a wearable device that discretely detects viral and bacterial infections and renders initial, broad-spectrum anti-viral or anti-bacterial treatment(s) at austere operational environments where no immediate medical countermeasures and no other detection capabilities are available until casualties are evacuated to locations with more robust medical resources for additional and specific differentiation and treatment. At a higher echelon of care, medical personnel must be able to receive data from the device to find out what category of threats (viral or bacterial) has triggered a biomarker detection and what corresponding treatments have been rendered to the affected force before providing more advanced care.

By continuously monitoring validated biomarkers, this device will empower warfighters to detect and respond to biological threats early, enhancing their survivability and operational effectiveness in high-threat theaters and mitigating risks to mission and force. This Air Force Medical Command initiative improves force health protection and ensures mission success. Dual-use functionality of this technology will focus on civilian healthcare systems.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Detection and Treatment of Traumatic Brain Injury in Military Working Dogs - SBIR DHA26BZ01-NV002

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $250,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Evaluate previously developed traumatic brain injury (TBI) detection and treatments methods that can be repurposed for use in military working dogs (MWDs) after suffering from battlefield injuries.

Description:

This topic is in support of the DoD Working Dog Strategic Research Plan concerning mitigation, strategies, and treatments for the detection and treatment of TBI.1 Due to the high-risk nature of MWD operations, TBI is a common injury. TBI in the MWD carries an extremely high mortality rate with a prehospital mortality of over 40% for severe TBI cases. It is estimated that 25-40% of all MWD trauma cases are accompanied by TBI, but there is limited data concerning the short- and long-term effects of TBI on the performance and health of the MWD. Current clinical detection methods for TBI in the MWD are by the observation of altered mentation (coma, stupor, depression, lethargy, inappropriate behavior or responses) of the MWD and by use of the modified veterinary Glasgow coma scale or with physical evidence of head trauma (e.g., lacerations, abrasions, bruising, swelling, pain, bleeding from the nose or ears). Current treatment guidelines for TBI in MWDs are largely based on treatment recommendations for humans and are primarily supportive measures to maintain blood pressure, oxygen levels, proper ventilation, and body temperature to mitigate secondary injuries2,3,4. There have been many TBI detection methods and treatment strategies developed for humans that have shown promising results in rodent and large animal models5. The objective of this SBIR is to review research that was performed in rodents, canines, or other large animal models that could be repurposed for the detection and treatment of TBI specifically in MWDs. This research topic does not support the use of canines for testing purposes. Any animal testing would require use of suitable animal model that would approximate the response of a canine.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Military Working Dog Whole Blood Product or Substitute - SBIR DHA26BZ01-NV001

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $250,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Develop a whole blood product or substitute to aid in hemorrhage control for Military Working Dogs (MWD) after battlefield injury that can be used near the point of injury (POI) and throughout the continuum of care to reduce morbidity and mortality.

Description:

This topic is in support of the DoD Working Dog Strategic Research Plan concerning solutions for bleeding control and coagulopathy support.1 The Military Working Dog (MWD) provides a unique and important service to the warfighter. MWDs serve as sentries, perform tracking and patrol, and are used for the detection of explosives. These activities come with a high risk of injury. Uncontrolled hemorrhage following traumatic injury accounts for over 45% of all MWD battlefield deaths2. The current standard of care for hemorrhage in the MWD is to provide immediate fluid therapy through the delivery of crystalloid fluids as the first-line treatment, which is then followed by a synthetic colloid or hypertonic saline. These treatments also require the administration of supplemental oxygen to maintain appropriate oxygen levels and for the survival of the MWD3. To improve their survival rates, the development of a shelf stable canine whole blood product or substitute is a critical priority

The goal of this topic is to develop a stable canine whole blood product and/or substitute (i.e. hemoglobin or polymer oxygen carriers), intended for canine use at both POI and throughout the continuum of care. The product should have a shelf-life of greater than 3 years and be thermal stable (-9℃ to 60℃) to ensure accessibility in operational environments. The product must primarily replicate the oxygen carrier characteristics of whole blood and demonstrate the ability to be used safely and effectively to treat blood loss following traumatic injury. This research topic does not support the use of canines for testing purposes. Any animal testing would require use of suitable animal models that would approximate the response of a canine.

Blood products derived from canine donors must be negative for canine red blood cell antigens DEA 1.1 and DEA 1.2. Donor animals must also be tested for blood borne diseases including canine brucellosis, hemobartonellosis, Borrelia burgdorferi (Lyme disease), Dirofilaria immitis (heartworm disease), Ehrlichia canis, Rocky Mountain spotted fever, Coccidioides immitis, Babesia canis, Babesia gibsoni, Mycoplasma haemocanis and plasma levels of von Willebrand factor. All donor animals must be current on immunizations for canine distemper, hepatitis, parainfluenza, leptospirosis, parvovirus, Bordatella, coronavirus and rabies virus as applicable.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II) - SBIR DHA26BZ01-DV005

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $1.3 Million

Deadline to Apply:

Est. April 29th, 2026.

Objective:

This topic is intended for technology proven ready to move directly into Phase II and accepts Direct to Phase II proposals only. The proposed research will focus on identifying compounds with broad-spectrum activity against clinically relevant fungal pathogens while minimizing toxicity to humans. The primary objective is to identify a small molecule with fungicidal properties that are safe for human use, with FDA clearance.

Description:

Fungal infections represent a growing global health challenge, particularly among immuno-compromised individuals. Invasive fungal infections caused by pathogens such as Candida species, Aspergillus species, Fusarium species, and Mucor species are associated with high morbidity and mortality rates. Fungal infections are associated with 130k hospitalizations, 13 million outpatient visits, and result in a financial burden of $19 billion on the civilian health care sector. Fungal wound infections in particular are also growing challenge for the military. Despite the availability of antifungal agents, current treatments are often limited by toxicity, drug resistance, and narrow-spectrum activity. The emergence of multidrug-resistant fungal strains, such as Candida auris, has further exacerbated the need for novel antifungal therapies. Small molecules with antifungal properties offer a promising avenue for addressing these challenges. Their ability to target specific fungal pathways, combined with the potential for oral bioavailability and low manufacturing costs, makes them ideal candidates for therapeutic development. However, significant scientific and technical hurdles remain with the discovery and optimization of small molecules that are both effective against fungal pathogens and safe for human use. Qualified proposals should identify small molecules with antifungal properties from an existing library. These small molecules should be active against all of the following fungi: Fusarium species, Aspergillus species, Candida auris, or Mucorales species. Qualified molecules will have antifungal activity at nanomolar concentrations. Further, these small molecules must have a cytotoxicity profile similar, or better than Amphotericin B.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below: